Аннотация:
Aim: to develop a personalized approach to the treatment of patients with psychostimulant dependence, taking into account the polymorphism of the brain neurotrophic factor (BDNF) gene.
Methods. The study included 305 patients with a diagnosis of psychostimulant dependence determined by the ICD-10 criteria, men and women aged 18 to 50 years, ethnic Russians who signed an informed consent. Genotyping was performed by polymerase chain reaction (PCR) from patients ‘ venous blood.
Results. Аll patients were divided into groups depending on the use of psychoactive substances (surfactants) and the presence of comorbid psychiatric pathology. In patients with the homozygous genotype (GG) of the rs6265 gene encoding BDNF, the duration of remissions is significantly longer (p<0.036), compared to patients with other genotypes of this gene. Compared to patients with genotypes GA and AA, patients with genotype gg, the rs6265 gene, completed a full course of medical rehabilitation in hospital settings, they had fewer breakdowns, and relapses of the disease were observed in isolated cases.
Conclusions. Based on the results obtained, clinical and genetic profiles of patients with certain parameters for clinical, personal and genetic components were identified. This will create a personalized approach to the treatment of patients with psychostimulant dependence and increase the effectiveness of treatment and rehabilitation measures.
Ключевые слова:
addiction of psychostimulants, a neurotrophic factor, personalized approach to rehabilitation.